A 3-month, phase III, open-label, single arm, multicenter study assessing the efficacy and safety of 0.5 mg ranibizumab monthly intravitreal injections as monotherapy in patients with visual impairment due to macular edema secondary to branch or central retinal vein occlusion (RVO)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Retinal oedema
Focus Registrational; Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

15 Aug 2014 New trial record
07 Feb 2013
17 Feb 2012

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight